Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
Our study provides new insights in MEF2C conservation and provides the first evidence of mef2cb regulation by both transcriptional and post transcriptional mechanisms.
mef2ca transcripts including exon 5 (mef2ca 4-5-6) are present early in the embryo. Over-expression of this isoform alters the expression of genes involved in early dorso-ventral patterning of the embryo and induces severe developmental defects
By selectively inhibiting translational initiation of mef2ca and other mRNAs, eIF4EBP3L reprograms the translational profile of muscle, enabling it to adjust to new environmental conditions.
find no evidence that the phenotypic stability in the wild type is provided by redundancy between mef2ca and its co-ortholog mef2cb, or that it is related to the selector (homeotic) gene function of mef2ca
Mef2ca single mutants have delayed heart development, but form an apparently normal heart. Mef2cb single mutants have a functional heart and are viable adults.
Data show that mef2cb is expressed in the late ventricular region, and is necessary for late myocardial addition to the arterial pole.
the genetic interaction of Tbx5 (show TBX5 Proteins) and Mef2c is not only required for MYH6 (show MYH6 Proteins) expression but also essential for the early stages of heart development and survival
Mef2c and Mef2d (show MEF2D Proteins) are required for proper cardiac gene expression.
MiR (show MLXIP Proteins)-135b-5p and MiR (show MLXIP Proteins)-499a-3p Promote Cell Proliferation and Migration in Atherosclerosis by Directly Targeting MEF2C
early B cell factor-1 (EBF1 (show EBF1 Proteins)) was identified as a co-regulator of gene expression with MEF2C.
Data show that high myocyte enhancer factor 2C (MEF2C) mRNA expression leads to overexpression of MEF2C protein, and these findings provide the rationale for therapeutic targeting of MEF2C transcriptional activation in acute myeloid leukemia (show BCL11A Proteins).
this is the first report of a Greek-Cypriot patient with a MEF2C-related phenotype highlighting the rich variability in phenotypic expression and the ethnic diversity associated with this condition.
BCL2 (show BCL2 Proteins) inhibitors may be a therapeutic candidate in vivo for patients with ETP-ALL with high expression levels of MEF2C.
MEF2C regulates the expression of G2/M checkpoint genes (14-3-3gamma (show YWHAG Proteins), Gadd45b (show GADD45B Proteins) and p21 (show CDKN1A Proteins)) and the sub-cellular localization of CYCLIN B1 (show CCNB1 Proteins).
The overall effect of MEF2C in hepatocellular carcinoma progression regulation was dictated by its subcellular distribution.
MEF2C/alpha-2-macroglobulin (show A2M Proteins) axis functions in endothelial cells as a negative feed-back mechanism that adapts sprouting activity to the oxygen concentration thus diminishing inappropriate and excess angiogenesis.
MEF2C and MEF2D interact with the E3 ligase F-box protein SKP2, which mediates their subsequent degradation through the ubiquitin-proteasome system.
Single nucleotide polymorphisms in ALDOB (show ALDOB Proteins), MAP3K1 (show MAP3K1 Proteins), and MEF2C are associated with cataract.
The cDNA sequence was analyzed and the 5' upstream region of the mef2c gene was isolated from porcine genomic DNA.
analysis of sequence and variations of the bovine myocyte enhancer factor 2C (MEF2C) gene promoter in Bos taurus cattle
Data show that three transcriptional factors Gata4 (show GATA4 Proteins), Mef2c, and Tbx5 (show TBX5 Proteins) (abbreviated as GMT (show GAMT Proteins)) significantly improved murine embryonic stem cells (ESCs (show NR2E3 Proteins)) differentiated into cardiomyocytes.
MEF2C has a role in regulating outflow tract alignment and transcriptional control of Tdgf1 (show TDGF1 Proteins)
These findings uncover a novel role for Mef2c/d in coordinating the transcriptional network that promotes early B-cell development.
our data indicate that robust hypertrophic MEF2 activation in the heart in vivo requires a background of adiponectin (show ADIPOQ Proteins) signaling and that adiponectin (show ADIPOQ Proteins) signaling in primary isolated CM directly enhances MEF2 activity through activation of p38 MAPK (show MAPK14 Proteins)
SmarcA4 (show SMARCA4 Proteins) is required for synapse development and myocyte enhancer factor 2-mediated synapse remodeling
Our results identify novel target genes for MEF2 and define MEF2 as an important regulator of Leydig cell function and male reproduction.
this is a novel mechanism of H2S-mediated activation of MEF2C and induction of miR (show MLXIP Proteins)-133a and inhibition of hypertrophy in HHcy cardiomyocytes.
The RBM4-MEF2C-miR-1 network constitutes a novel mechanism which programs the gene expression profile toward the development of brown adipocytes.
increased sclerostin (show SOST Proteins) production achieved by HDAC5 (show HDAC5 Proteins) shRNA is abrogated by simultaneous knockdown of MEF2C, indicating that MEF2C is a major target of HDAC5 (show HDAC5 Proteins) in osteocytes
Endothelin signaling activates Mef2c expression in the neural crest through a MEF2C-dependent positive-feedback transcriptional pathway.
This locus encodes a member of the MADS box transcription enhancer factor 2 (MEF2) family of proteins, which play a role in myogenesis. The encoded protein, MEF2 polypeptide C, has both trans-activating and DNA binding activities. This protein may play a role in maintaining the differentiated state of muscle cells. Mutations and deletions at this locus have been associated with severe mental retardation, stereotypic movements, epilepsy, and cerebral malformation. Alternatively spliced transcript variants have been described.
myocyte-specific enhancer factor 2C
, myocyte enhancer factor 2C
, myocyte-specific enhancer factor 2C-like
, MADS box transcription enhancer factor 2, polypeptide C
, MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)
, Myocyte enhancer factor 2C protein
, myocyte enhancer factor 2c